Former executives at Johnson & Johnson (NYSE: JNJ) have teamed up to launch a new biotech company, Third Arc Bio, with significant backing from investors. 24 July 2024
Australian radiopharma developer Telix Pharmaceuticals Limited has launched an offering of A$600 million ($405 million) of convertible notes due 2029. 24 July 2024
Brenig Therapeutics, a neurology-focused drug development company using an AI-based discovery platform, has closed a $65 million series A financing. 24 July 2024
Tuesday was not a good day for shareholders in US biopharma Cellectar Biosciences—a US biopharma focused on the discovery, development and commercialization of drugs for the treatment of cancer. 23 July 2024
Cambridge, USA-based biotech incubator Flagship Pioneering today unveiled Abiologics, a company reimagining biologics with the creation of a new class of supranatural and programmable medicines, called Synteins. 23 July 2024
UK-based Touchlight, a CDMO advancing enzymatic DNA production to enable the genetic medicine revolution, has announced a license agreement with London-based pharma major GSK (LSE: GSK). 23 July 2024
Latigo Biotherapeutics, a privately-held US biotech focused on developing non-opioid pain medicines, has appointed Nima Farzan as chief executive. 23 July 2024
In San Francisco, RAPT Therapeutics (Nasdaq: RAPT) has announced a substantial workforce reduction as part of its cash conservation strategy. 23 July 2024
SIGA Technologies (Nasdaq: SIGA) has announced a significant procurement option exercised by the US health authorities, an order for $113 million worth of oral Tpoxx (tecovirimat). 23 July 2024
California-based liver and viral disease specialist Aligos Therapeutics (Nasdaq: ALGS) has announced a clinical trial collaboration with Amoytop Biotech. 23 July 2024
Ardelyx has filed a lawsuit against the US Department of Health and Human Services DHSS) and the Centers for Medicare and Medicaid Services (CMS), regarding its Xpohzah. 19 July 2024
Californian start-up Caribou Biosciences (Nasdaq: CRBU) has announced significant workforce reductions, cutting approximately 12% of its staff. 19 July 2024
Boston, USA-based AVEO Oncology, a subsidiary of LG Chem (KRX: 051910), has announced that the TiNivo-2 Phase III trial did not meet its primary efficacy endpoint. 19 July 2024
Swedish firm Enzymatica (STO: ENZY) will conduct a rights issue to raise approximately $12 million, with existing shareholders being given preferential rights. 18 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024